Upcoming Hypercortisolism And Oncology Approvals Will Transform This Cortisol Modulation Leader

Catalysts

About Corcept Therapeutics

Corcept Therapeutics develops selective cortisol modulators to treat serious endocrine, metabolic and oncologic diseases.

What are the underlying business or industry changes driving this perspective?

• Impending FDA decisions for relacorilant in hypercortisolism and platinum resistant ovarian cancer, alongside a European approval process, create a visible path to multiple new product launches that could substantially expand revenue and earnings power over the next several years.
• Rapidly growing recognition of hypercortisolism in difficult to treat diabetes and hypertension, reinforced by the CATALYST and upcoming MOMENTUM data, supports a much larger diagnosable patient pool. This can drive sustained prescription growth and higher long term revenue.
• Relacorilant's strong efficacy and tolerability profile versus current options, together with management’s expectation that most Korlym patients will transition, positions the company to deepen its leadership in Cushing's syndrome. It also has the potential to materially improve net margins as the franchise scales.
• Expanding oncology programs across ovarian, endometrial, cervical, pancreatic and other solid tumors, combined with guideline oriented trial designs, provide a roadmap to transform relacorilant and follow on agents into multi indication oncology platforms. This can meaningfully increase total company revenue and earnings.
• Advancement of miricorilant in MASH and dazucorilant in ALS, both addressing large unmet need populations where early data show compelling signals, offers additional late stage pipeline shots on goal. This can diversify cash flows and enhance long term margin and earnings growth.

Assumptions

This narrative explores a more optimistic perspective on Corcept Therapeutics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Corcept Therapeutics's revenue will grow by 37.5% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 14.1% today to 36.8% in 3 years time.
• The bullish analysts expect earnings to reach $708.3 million (and earnings per share of $5.51) by about January 2029, up from $104.7 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $628.8 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 21.8x on those 2029 earnings, down from 38.4x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.9x.
• The bullish analysts expect the number of shares outstanding to decline by 0.3% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The appeal against Teva regarding Korlym's patents may be unsuccessful or result in a limited outcome, which could enable sustained or increased generic competition over time and structurally cap pricing power and revenue growth from the legacy hypercortisolism franchise, placing long term pressure on earnings.
• The bullish thesis relies heavily on multiple regulatory approvals and pivotal readouts for relacorilant, miricorilant and dazucorilant across endocrine, oncology, MASH and ALS. Any delay, negative data, safety signal or complete response letter from the FDA or EMA would undermine the multi indication expansion narrative and materially reduce projected revenue and earnings growth.
• The company is rapidly scaling its commercial footprint and clinical portfolio, which requires persistently higher SG&A and R&D investment. If physician uptake, guideline inclusion and real world utilization of new indications lag expectations, fixed costs could rise faster than sales and compress net margins and free cash flow for an extended period.
• Long term capacity and distribution constraints in the specialty pharmacy network, combined with a growing mix of lower priced authorized generics and potential future payor pushback in an increasingly cost sensitive healthcare environment, could limit realized net pricing, constrain volume growth and weigh on gross margin and overall profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Corcept Therapeutics is $121.0, which represents up to two standard deviations above the consensus price target of $91.0. This valuation is based on what can be assumed as the expectations of Corcept Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $121.0, and the most bearish reporting a price target of just $50.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $1.9 billion, earnings will come to $708.3 million, and it would be trading on a PE ratio of 21.8x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $38.2, the analyst price target of $121.0 is 68.4% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.